Sunmax Biotechnology Co Ltd (4728) — Cash Flow-to-Debt Ratio
Sunmax Biotechnology Co Ltd (4728) has a Cash Flow-to-Debt Ratio of 0.35x as of September 2025, meaning its operating cash flow of NT$160.84 Million could theoretically repay 0% of its total liabilities (NT$454.35 Million) in one year. See Sunmax Biotechnology Co Ltd free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sunmax Biotechnology Co Ltd Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Sunmax Biotechnology Co Ltd across 10 annual periods. For the full cash flow conversion analysis, see 4728 cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Sunmax Biotechnology Co Ltd (2015–2024)
Year-by-year debt coverage analysis for Sunmax Biotechnology Co Ltd. Check 4728 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 1.18x | NT$397.37 Million | NT$337.82 Million | ▲ +1.6% |
| 2023 | 1.16x | NT$848.56 Million | NT$732.99 Million | ▲ +58.0% |
| 2022 | 0.73x | NT$342.97 Million | NT$468.00 Million | ▲ +38.7% |
| 2021 | 0.53x | NT$243.28 Million | NT$460.44 Million | ▼ -35.1% |
| 2020 | 0.81x | NT$386.97 Million | NT$475.27 Million | ▲ +22.6% |
| 2019 | 0.66x | NT$289.51 Million | NT$435.82 Million | ▼ -27.6% |
| 2018 | 0.92x | NT$100.83 Million | NT$109.88 Million | ▲ +118.2% |
| 2017 | 0.42x | NT$37.09 Million | NT$88.22 Million | ▲ +7.0% |
| 2016 | 0.39x | NT$16.58 Million | NT$42.20 Million | ▲ +176.3% |
| 2015 | -0.52x | NT$-22.84 Million | NT$44.33 Million | — |